Nonopioid Medication Overuse Headache Remission Observed With Erenumab

Published Date: 31 Oct 2024

Over months 4 through 6, 69.1% of participants on erenumab 140 mg, and 60.3% of the erenumab 70 mg group achieved MOH remission compared with 52.6% of those on placebo

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

2.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

3.

Millions of men could benefit from faster scan to diagnose prostate cancer

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot